Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InterMune, a biotechnology company, has announced the pricing of an underwritten public offering of 3.5 million shares of its common stock. The last reported sale price of InterMune's common stock on the Nasdaq global select market on February 12, 2009 was $17.96.
Subscribe to our email newsletter
The offering is expected to close on or about February 19, 2009, subject to customary closing conditions. All of the shares are being sold by the company.
UBS Investment Bank is the sole manager for the offering. InterMune has granted the underwriter a 30-day option to purchase up to an additional 525,000 shares to cover over-allotments, if any.